Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database

This publication has 28 references indexed in Scilit:

• Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology
  Virchows Archiv, 2009
• Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression
  International Journal of Cancer, 2008
• Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy
  Annals of Surgical Oncology, 2007
• The correlation of regression in primary melanoma with sentinel lymph node status
  Journal of Clinical Pathology, 2007
• High positive sentinel node identification rate by EORTC melanoma group protocol
  European Journal of Cancer, 2006
• Sentinel Node Biopsy Provides More Accurate Staging Than Elective Lymph Node Dissection in Patients With Cutaneous Melanoma
  Annals of Surgical Oncology, 2004
• Lymphatic Mapping and Sentinel Lymphadenectomy for Early-Stage Melanoma
  Annals of Surgery, 2003
• Clinical Outcome of Stage I/II Melanoma Patients After Selective Sentinel Lymph Node Dissection: Long-Term Follow-Up Results
  Journal of Clinical Oncology, 2003
• Lack of Relevant Information for Tumor Staging in Pathology Reports of Primary Cutaneous Melanoma
  American Journal of Clinical Pathology, 2001
• Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
  JNCI: Journal of the National Cancer Institute, 1989